
Novartis’ heart failure drug Entresto gets top US, EU recommendation
pharmafile | May 23, 2016 | News story | Research and Development, Sales and Marketing |Â Â Ernesto, Novartis, heart failure, regulationÂ
Swiss drugmaker Novartis (VTX: NOVN) said its heart failure drug Entresto (sacubitril/ valsartan) has secured top recommendations in the US and EU.
The company said Entresto has won Class I recommendation from the American College of Cardiology (ACC), the American Heart Association (AHA) and the Heart Failure Society of America (HFSA) in the US, and the European Society of Cardiology in the EU.
Entresto is now a standard therapy for heart failure with reduced ejection fraction (HFrEF) as an alternative to an ACE inhibitor, in the US, Novartis said.
Heart failure is a debilitating and life-threatening condition, which impacts over 60 million people worldwide. It is the leading cause of hospitalization in people over the age of 65. About half of people with heart failure have HFrEF. Reduced ejection fraction means the heart does not contract with enough force, so less blood is pumped out. Heart failure presents a major and growing health-economic burden that currently costs the world economy $108 billion every year.
Anjali Shukla
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

First malaria medicine for infants under 4.5kg receives approval
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …






